BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 5, 2016--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing CODIT™ (characterized oral desensitization immunotherapy)
treatments for life-threatening food allergies, today announced the
appointment of Douglas Sheehy as General Counsel and Secretary. Mr.
Sheehy has more than 20 years of both in-house and law firm experience,
including nearly a decade as general counsel.
“As Aimmune experiences rapid growth, we’re committed to continuing to
operate with the highest integrity and to upholding the best practices
of corporate governance and compliance across all of our functions —
clinical development, research, regulatory, and financial and commercial
operations. Doug has proven sound judgment in meeting critical business
objectives, and he will be a key contributor as we move forward,” said
Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D.
Mr. Sheehy joins Aimmune from Codexis, Inc., a developer of biocatalysts
for the pharmaceutical and fine chemical industries, where he was hired
as General Counsel and Secretary in 2007. Most recently, he was also the
company’s Chief Administrative Officer. Previously, Mr. Sheehy spent
five years in key legal roles at CV Therapeutics, Inc., a publicly held
biopharmaceutical company that was subsequently acquired by Gilead in
2009. He began his legal career as a corporate attorney at Gunderson
Dettmer LLP. Mr. Sheehy holds a B.A. in history from Dartmouth College
and a J.D. from American University, where he served as Editor-in-Chief
of the Law Review.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s CODIT™ (characterized oral desensitization immunotherapy)
system uses rigorously characterized product candidates with gradual,
controlled up-dosing protocols to obtain clinically meaningful
desensitization to food allergens. Aimmune’s first CODIT product, AR101
for the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age. Aimmune’s Phase 3 trial of AR101, PALISADE, is now
enrolling patients. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160405005665/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,